Overview
- The plant will rise in Fogelsville in Pennsylvania’s Lehigh Valley, just west of Allentown.
- Lilly projects roughly 800–850 permanent jobs, with construction beginning in 2026 and operations targeted for 2031.
- The facility will make injectable medicines and devices, including the weight-loss candidate retatrutide, which has not yet been approved.
- The selection completes the fourth of Lilly’s pledged U.S. mega-sites under a $27 billion program to expand manufacturing.
- The company cites strong demand for Zepbound and Mounjaro and past shortages as drivers, and plans AI-enabled production and partnerships with local universities to build talent.